The Good
Clearly labels CD19+ B cells.
The Bad
There are brighter antibodies directed against CD19.
The Bottom Line
Because this antibody isn't as bright as some other available CD19 antibodies, it can be useful in instances where a lot of other channels are being engaged, so the downstream compensation will not be as significant. However, if one needs to robustly distinguish B cells from non-B cells to remove potentially confounding populations, a brighter antibody may be more useful.